Molecular Pathways and Therapeutic Targets in Pediatric Gliomas

Pediatric gliomas comprise a spectrum of brain tumours driven by distinct genetic and epigenetic alterations that converge on chromatin regulation, growth-factor signalling and cell-cycle control. Recurrent lysine-to-methionine substitutions in histone H3 variants (notably H3K27M and H3G34R/V) disrupt the activity of the Polycomb repressive complex 2, leading to widespread loss of H3K27 trimethylation and aberrant gene expression programmes. Concurrent alterations in receptor tyrosine kinases (PDGFRA, FGFR1, ACVR1) activate downstream PI3K/Akt/mTOR and RAS/MAPK cascades, while mutations in cell-cycle regulators (CDK4/6, Ink4a-ARF) override mitotic checkpoints. The unique non-inflammatory microenvironment of diffuse intrinsic pontine glioma (DIPG) further complicates immune-based approaches. Recent studies have underscored the efficacy of blood-brain-barrier-penetrant kinase inhibitors, combinatorial epigenetic therapies and metabolism-modulating agents, offering a path towards subtype-specific intervention and improved clinical outcomes.

Research from Nature Portfolio

Spatial analysis of driver mutations in paediatric high-grade and midline gliomas has revealed that H3K27M alterations and their obligate partner mutations (in TP53/PPM1D or ACVR1/PIK3R1) are ubiquitously present across primary and metastatic sites, underscoring the suitability of limited biopsies to guide targeted therapy. Foundational work on H3K27M-mutant cultures has demonstrated that the mutation impairs the spreading of PRC2-mediated H3K27me2/3 marks without altering PRC2 recruitment, and that genetic removal of the oncohistone restores repressive chromatin domains, halts proliferation and abolishes tumour formation in vivo. These insights into homogeneity of key epigenetic drivers and mechanisms of chromatin dysregulation provide a robust framework for the development of therapies aimed at restoring normal histone methylation patterns.

Molecular Pathways and Therapeutic Targets in Pediatric Gliomas publication trend

The graph below shows the total number of articles in molecular pathways and therapeutic targets in pediatric gliomas across all publications each year (not limited to Nature Index journals).

Technical terms

H3K27M mutation: A lysine-to-methionine substitution in histone H3 impairing PRC2-mediated trimethylation and altering chromatin repression.

PRC2: Polycomb repressive complex 2, an epigenetic writer that deposits repressive H3K27me2/3 marks to silence gene expression.

Diffuse intrinsic pontine glioma (DIPG): A lethal paediatric brainstem tumour characterised by H3K27M mutations and an immunologically cold microenvironment.

PI3K/Akt/mTOR pathway: A central growth-factor signalling network regulating cell proliferation, survival and metabolism.

Epigenetic reprogramming: Alteration of chromatin marks and gene-expression programmes without changes to DNA sequence.

Receptor tyrosine kinase (RTK): A class of cell-surface receptors (e.g., PDGFRA, FGFR1) that activates intracellular signalling cascades upon ligand binding.

References

1. A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities. Cancer Discovery (2023).
2. PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma. Journal of Clinical Investigation (2024).
3. Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. Cancer Cell (2017).
4. Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. Nature Communications (2016).
5. H3K27M induces defective chromatin spread of PRC2-mediated repressive H3K27me2/me3 and is essential for glioma tumorigenesis. Nature Communications (2019).
6. Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma. Acta Neuropathologica Communications (2018).